IFN-λ及其抗病毒作用机制  

IFN-λ and its antiviral mechanism

作　　者：陈薇[1] 赵俊[2] 王明丽[2] 

机构地区：[1]安徽医科大学第一临床医学院,合肥230032 [2]安徽医科大学第一临床医学院微生物学教研室,合肥230032

出　　处：《国际生物制品学杂志》2016年第1期38-43,共6页International Journal of Biologicals

基　　金：国家自然科学基金（30872253）;安徽省科技厅科技攻关项目（08010302179）

摘　　要：最近发现的Ⅲ型IFN家族由IFN-λ1、IFN-λ2、IFN-λ3（也称作IL-29、IL-28A、IL-28B）和IFN-λ4组成。IFN-λ通过结合IFN-λR1和IL-10R2组成的异二聚体受体复合物，激活Janus激酶一信号转导及转录活化因子信号通路，诱导IFN刺激基因的表达并发挥生物学作用。近年来，对IFN-λ抗病毒作用的研究十分广泛，IFNλ与HCV感染引起的免疫应答密切相关。IL-28B的单核苷酸多态性和新发现的IFN-λ4与HCV的自发清除也有关，预示IFN-λ在HCV感染治疗中具有潜在作用。此文介绍了IFM-λ的抗病毒作用机制及其在HCV感染临床治疗中的研究进展。Type-Ⅲ IFN family, composed of IFN-λ1, IFN-λ2, IFN-λ3 （also named as IL-29, IL-28A, IL-28B） and IFN-λ4, is recently identified. IFN-λs bind a heterodimeric receptor complex of IFN-λR1 and IL-10R2 to activate Janus kinase-signal transducer and activator of transcription pathway to induce the expression of IFN-stimulated genes, ultimately leading to biological functions. Recently, the antiviral activity of IFN-λs has been studied extensively and evidence suggests that IFN-λs are intimately associated with the immune response to HCV infection. Additionally, IL-28B polymorphisms and the newly described IFN-λ4 are linked to spontaneous clearance of HCV, suggesting potential roles of IFN-λs in HCV infection therapy. This review summarizes research progress of antiviral mechanism of IFN-λs and their clinical application in the therapy of HCV infection.

关 键 词：干扰素类 白细胞介素类 抗病毒药 肝炎 丙型 

分 类 号：R752.11[医药卫生—皮肤病学与性病学]